Bivalirudin With Prolonged Full Dose Infusion Versus Heparin Alone During Emergency PCI
Status:
Recruiting
Trial end date:
2024-12-31
Target enrollment:
Participant gender:
Summary
This study is aimed to investigate if the bivaliruding with prolonged full dose infusion
after PCI is superior to heparin alone in reducing 30-day mortality or major bleeding for
patients with STEMI treated with emergency PCI. A total of 6000 STEMI patients will be
enrolled and randomly assigned to receive bivalirudin or heparin during emergency PCI in a
1:1 ratio. This study will provide key evidence for peri-operative anticoagulant therapy
decisions in STEMI patients.